Mutations	mutations	O	O	O	O
associated	associated	O	O	O	O
with	with	O	O	O	O
lamivudine-resistance	lamivudine-resistance	O	O	O	O
in	in	O	O	O	O
therapy-na	therapy-na	O	O	O	O
 	 	O	O	O	O
ve	ve	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus	virus	O	O	OTHERS	I
(	(	O	O	OTHERS	I
HBV	hbv	O	O	OTHERS	I
)	)	O	O	OTHERS	I
infected	infected	O	O	OTHERS	I
patients	patients	O	O	O	O
with	with	O	O	O	O
and	and	O	O	O	O
without	without	O	O	O	O
HIV	hiv	O	O	O	O
co-infection	co-infection	O	O	O	O
:	:	O	O	O	O
implications	implications	O	O	O	O
for	for	O	O	O	O
antiretroviral	antiretroviral	O	O	O	O
therapy	therapy	O	O	O	O
in	in	O	O	O	O
HBV	hbv	O	O	O	O
and	and	O	O	O	O
HIV	hiv	O	O	O	O
co-infected	co-infected	O	O	O	O
South	south	O	O	O	O
African	african	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

This	this	O	O	O	O
was	was	O	O	O	O
an	an	O	O	O	O
exploratory	exploratory	O	O	O	O
study	study	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
lamivudine-resistant	lamivudine-resistant	O	O	O	O
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
virus	virus	O	O	O	O
(	(	O	O	O	O
HBV	hbv	O	O	O	O
)	)	O	O	O	O
strains	strains	O	O	O	O
in	in	O	O	O	O
selected	selected	O	O	O	O
lamivudine-na	lamivudine-na	O	O	O	O
 	 	O	O	O	O
ve	ve	O	O	O	O
HBV	hbv	O	O	O	O
carriers	carriers	O	O	O	O
with	with	O	O	O	O
and	and	O	O	O	O
without	without	O	O	O	O
human	human	O	O	OTHERS	I
immunodeficiency	immunodeficiency	O	O	OTHERS	I
virus	virus	O	O	OTHERS	I
(	(	O	O	O	O
HIV	hiv	O	O	O	O
)	)	O	O	O	O
co-infection	co-infection	O	O	O	O
in	in	O	O	O	O
South	south	O	O	O	O
African	african	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Thirty-five	thirty-five	O	O	O	O
lamivudine-na	lamivudine-na	O	O	O	O
 	 	O	O	O	O
ve	ve	O	O	O	O
HBV	hbv	O	O	OTHERS	I
infected	infected	O	O	OTHERS	I
patients	patients	O	O	O	O
with	with	O	O	O	O
or	or	O	O	O	O
without	without	O	O	O	O
HIV	hiv	O	O	O	O
co-infection	co-infection	O	O	O	O
were	were	O	O	O	O
studied	studied	O	O	O	O
:	:	O	O	O	O
15	15	O	O	O	O
chronic	chronic	O	O	O	O
HBV	hbv	O	O	O	O
mono-infected	mono-infected	O	O	O	O
patients	patients	O	O	O	O
and	and	O	O	O	O
20	20	O	O	O	O
HBV-HIV	hbv-hiv	O	O	O	O
co-infected	co-infected	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
latter	latter	O	O	O	O
group	group	O	O	O	O
was	was	O	O	O	O
further	further	O	O	O	O
sub-divided	sub-divided	O	O	O	O
into	into	O	O	O	O
13	13	O	O	O	O
occult	occult	O	O	O	O
HBV	hbv	O	O	O	O
(	(	O	O	O	O
HBsAg-negative	hbsag-negative	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
7	7	O	O	O	O
overt	overt	O	O	O	O
HBV	hbv	O	O	O	O
(	(	O	O	O	O
HBsAg-	hbsag-	O	O	O	O
positive	positive	O	O	O	O
)	)	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

HBsAg	hbsag	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
anti-HBs	anti-hbs	O	O	O	O
,	,	O	O	O	O
anti-HBc	anti-hbc	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
anti-HIV	anti-hiv	O	O	O	O
1/2	1/2	O	O	O	O
were	were	O	O	O	O
determined	determined	O	O	O	O
as	as	O	O	O	O
part	part	O	O	O	O
of	of	O	O	O	O
routine	routine	O	O	O	O
diagnosis	diagnosis	O	O	O	O
using	using	O	O	O	O
Axsym	axsym	O	O	O	O
assays	assays	O	O	O	O
(	(	O	O	O	O
Abbott	abbott	O	O	O	O
Laboratories	laboratories	O	O	O	O
,	,	O	O	O	O
North	north	O	O	O	O
Chicago	chicago	O	O	O	O
,	,	O	O	O	O
IL	il	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Serum	serum	O	O	O	O
samples	samples	O	O	O	O
were	were	O	O	O	O
PCR	pcr	O	O	O	O
amplified	amplified	O	O	O	O
with	with	O	O	O	O
HBV	hbv	O	O	O	O
reverse	reverse	O	O	O	O
transcriptase	transcriptase	O	O	O	O
(	(	O	O	O	O
RT	rt	O	O	O	O
)	)	O	O	O	O
primers	primers	O	O	O	O
,	,	O	O	O	O
followed	followed	O	O	O	O
by	by	O	O	O	O
direct	direct	O	O	O	O
sequencing	sequencing	O	O	O	O
across	across	O	O	O	O
the	the	O	O	O	O
tyrosine-methionine-aspartate-aspartate	tyrosine-methionine-aspartate-aspartate	O	O	O	O
(	(	O	O	O	O
YMDD	ymdd	O	O	O	O
)	)	O	O	O	O
motif	motif	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
major	major	O	O	O	O
catalytic	catalytic	O	O	O	O
region	region	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
C	c	O	O	OTHERS	I
domain	domain	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
HBV	hbv	O	O	O	O
RT	rt	O	O	O	O
enzyme	enzyme	O	O	O	O
.	.	O	O	O	O

HBV	hbv	O	O	O	O
viral	viral	O	O	O	O
load	load	O	O	O	O
was	was	O	O	O	O
performed	performed	O	O	O	O
with	with	O	O	O	O
Amplicor	amplicor	O	O	O	O
HBV	hbv	O	O	O	O
Monitor	monitor	O	O	O	O
test	test	O	O	O	O
v2.0	v2.0	O	O	O	O
(	(	O	O	O	O
Roche	roche	O	O	O	O
Diagnostics	diagnostics	O	O	O	O
,	,	O	O	O	O
Penzberg	penzberg	O	O	O	O
,	,	O	O	O	O
Germany	germany	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

HBV	hbv	O	O	O	O
lamivudine-resistant	lamivudine-resistant	O	O	O	O
strains	strains	O	O	O	O
were	were	O	O	O	O
detected	detected	O	O	O	O
in	in	O	O	O	O
3	3	O	O	O	O
of	of	O	O	O	O
15	15	O	O	O	O
mono-infected	mono-infected	O	O	O	O
chronic	chronic	O	O	OTHERS	I
hepatitis	hepatitis	O	DISEASE	OTHERS	I
B	b	O	DISEASE	OTHERS	I
patients	patients	O	O	O	O
and	and	O	O	O	O
10	10	O	O	O	O
of	of	O	O	O	O
20	20	O	O	O	O
HBV-HIV	hbv-hiv	O	O	O	O
co-infected	co-infected	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

To	to	O	O	O	O
the	the	O	O	O	O
best	best	O	O	O	O
of	of	O	O	O	O
our	our	O	O	O	O
knowledge	knowledge	O	O	O	O
,	,	O	O	O	O
this	this	O	O	O	O
constitutes	constitutes	O	O	O	O
the	the	O	O	O	O
first	first	O	O	O	O
report	report	O	O	O	O
of	of	O	O	O	O
HBV	hbv	O	O	O	O
lamivudine-resistant	lamivudine-resistant	O	O	O	O
strains	strains	O	O	O	O
in	in	O	O	O	O
therapy-na	therapy-na	O	O	O	O
 	 	O	O	O	O
ve	ve	O	O	O	O
HBV-HIV	hbv-hiv	O	O	O	O
co-infected	co-infected	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
HBV	hbv	O	O	O	O
viral	viral	O	O	O	O
loads	loads	O	O	O	O
for	for	O	O	O	O
mono-infected	mono-infected	O	O	O	O
and	and	O	O	O	O
co-infected	co-infected	O	O	O	O
patients	patients	O	O	O	O
ranged	ranged	O	O	O	O
from	from	O	O	O	O
3.32	3.32	O	O	O	O
x	x	O	O	O	O
10(2	10(2	O	O	O	O
)	)	O	O	O	O
to	to	O	O	O	O
3.82	3.82	O	O	O	O
x	x	O	O	O	O
10(7	10(7	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
<	<	O	O	O	O
200	200	O	O	O	O
to	to	O	O	O	O
4.40	4.40	O	O	O	O
x	x	O	O	O	O
10(3	10(3	O	O	O	O
)	)	O	O	O	O
copies/ml	copies/ml	O	O	O	O
,	,	O	O	O	O
respectively	respectively	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
remains	remains	O	O	O	O
to	to	O	O	O	O
be	be	O	O	O	O
seen	seen	O	O	O	O
whether	whether	O	O	O	O
such	such	O	O	O	O
pre-existing	pre-existing	O	O	O	O
antiviral	antiviral	O	O	O	O
mutations	mutations	O	O	O	O
could	could	O	O	O	O
result	result	O	O	O	O
in	in	O	O	O	O
widespread	widespread	O	O	O	O
emergence	emergence	O	O	O	O
of	of	O	O	O	O
HBV	hbv	O	O	O	O
resistant	resistant	O	O	O	O
strains	strains	O	O	O	O
when	when	O	O	O	O
lamivudine-containing	lamivudine-containing	O	O	O	O
highly	highly	O	O	O	O
active	active	O	O	O	O
antiretroviral	antiretroviral	O	O	O	O
(	(	O	O	O	O
ARV	arv	O	O	O	O
)	)	O	O	O	O
treatment	treatment	O	O	O	O
(	(	O	O	O	O
HAART	haart	O	O	O	O
)	)	O	O	O	O
regimens	regimens	O	O	O	O
become	become	O	O	O	O
widely	widely	O	O	O	O
applied	applied	O	O	O	O
in	in	O	O	O	O
South	south	O	O	O	O
Africa	africa	O	O	O	O
,	,	O	O	O	O
as	as	O	O	O	O
this	this	O	O	O	O
is	is	O	O	O	O
likely	likely	O	O	O	O
to	to	O	O	O	O
have	have	O	O	O	O
potential	potential	O	O	O	O
implications	implications	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
HBV-HIV	hbv-hiv	O	O	O	O
co-infected	co-infected	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

